Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

July 21, 2018

Chicago, Illinois

Continuing Education

Continuing Medical Education

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACCMEMaintenance of Certification
Successful completion of this CME activity enables a participant to earn MOC points towards the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points. The deadline to claim MOC points is September 21, 2018.>

Imedex®, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This live knowledge-based activity (Universal Activity Number JA0006201-9999-18-045-L01-P) has been approved for a maximum of 6.5 contact hours (0.65 CEUs).

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system. The deadline to claim credit is September 21, 2018. Following ACPE Policy, NACCME will not be able to report your claimed credit to CPE Monitor after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of an evaluation for each activity or session attended.

In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NACCME has been authorized by the American Academy of PAs (APA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 6.5 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.

Who Should Attend

This educational activity is specifically designed for gastroenterologists, hospitalists, internal medicine specialists, and other healthcare professionals (physicians-in-training, nurses, pharmacists, physicians assistants, etc.) involved and/or interested in the therapeutic management of patients with IBD.


After successful completion of this activity, participants should be able to:

  • Assess the mechanism of action and therapeutic potential of evolving treatments in IBD
  • Evaluate strategies for sequencing therapeutics in the era of biologics, immunotherapies and biosimilars
  • Identify a personalized therapeutic approach to optimally manage complex cases of CD
  • Interpret pivotal clinical trial data and novel management strategies for integration into clinical practice
  • Describe therapeutic strategies designed to prevent infections and extraintestinal manifestations in IBD
  • Define the role of treat-to-target in IBD regimens designed to maximize the opportunity to achieve remission and avoid relapse
  • Identify strategies to de-escalate therapy once remission is achieved in IBD
  • Assess the emerging role of biosimilars in IBD therapy, and their integration into current standards of care